The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology

Human Pathology

Volumn 42, Issue 3, 2011, Pages 303-314

  Findeis Hosey, Jennifer J ^a   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dysplasia; IGF2BP3; IMP3; KOC; L523S; Malignancy; Oncoprotein; Prognosis; Survival

Indexed keywords

MESSENGER RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; BENIGN TUMOR; BILE DUCT CARCINOMA; BILE DUCT INJURY; CANCER GRADING; CANCER SURGERY; CARCINOID; DIAGNOSTIC ACCURACY; DYSPLASIA; EFFUSION; ENDOCRINE TUMOR; ESOPHAGEAL DYSPLASIA; FOLLICULAR CARCINOMA; GERMINAL CENTER; HUMAN; HYPERPLASIA; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NEVUS; PANCREAS CARCINOMA; PANCREATOBILIARY DYSPLASIA; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TUMOR BIOPSY; UROTHELIAL DYSPLASIA; UTERINE CERVIX ADENOCARCINOMA;

ADENOMA, LIVER CELL; CARCINOID TUMOR; CARCINOMA, HEPATOCELLULAR; CARCINOMA, NEUROENDOCRINE; CARCINOMA, PANCREATIC DUCTAL; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIVER NEOPLASMS; LYMPHOMA; MALE; MESOTHELIOMA; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79951581469     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.06.003     Document Type: Article

References (80)

1. Mueller-Pillasch F., Lacher U., and Wallrapp C. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain conta (Pubitemid 27283112)
2. Nielsen J., Christiansen J., and Lykke-Andersen J. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development Mol Cell Biol 19 1999 1262 1270 (Pubitemid 29046868)
3. Yaniv K., and Yisraeli J.K. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis Gene 287 2002 49 54 (Pubitemid 34460566)
4. Liao B., Hu Y., Herrick D.J., and Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells J Biol Chem 280 2005 18517 18524 (Pubitemid 41389102)
5. Vikesaa J., Hansen T.V., and Jonson L. RNA-binding IMPs promote cell adhesion and invadopodia formation EMBO J 25 2006 1456 1468
6. Jeng Y.M., Chang C.C., and Hu F.C. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma Hepatol 48 2008 1118 1127
7. Kabbarah O., Nogueira C., and Feng B. Integrative genome comparison of primary and metastatic melanomas PLoS One 5 2010 e10770
8. Mueller-Pillasch F., Pohl B., and Wilda M. Expression of the highly conserved RNA binding protein KOC in embryogenesis Mech Dev 88 1999 95 99 (Pubitemid 29467415)
9. Wang T., Fan L., and Watanabe Y. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer Br J Cancer 88 2003 887 894 (Pubitemid 36520876)
10. Hammer N.A., Hansen T.O., and Byskov A.G. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer Reproduction 130 2005 203 212 (Pubitemid 41149808)
11. Kobel M., Xu H., and Bourne P.A. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype Mod Pathol 22 2009 469 475
12. Yantiss R.K., Woda B.A., and Fanger G.R. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas Am J Surg Pathol 29 2005 188 195 (Pubitemid 40170636)
13. Simon R., Bourne P.A., and Yang Q. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not Hum Pathol 38 2007 1178 1183 (Pubitemid 47058168)
14. Pryor J.G., Simon R.A., and Bourne P.A. Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas Hum Pathol 40 2009 238 243
15. Righi A., Zhang S., and Jin L. Analysis of IMP3 expression in normal and neoplastic human pituitary tissues Endocr Pathol 21 2010 25 31
16. King R.L., Pasha T., Roullet M.R., Zhang P.J., and Bagg A. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue Hum Pathol 40 2009 1699 1705
17. Monk D., Bentley L., and Beechey C. Characterization of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome J Med Genet 39 2002 575 581 (Pubitemid 34864561)
18. Gress T.M., Muller-Pillasch F., and Geng M. A pancreatic cancer-specific expression profile Oncogene 13 1996 1819 1830 (Pubitemid 26377516)
19. Schaeffer D.F., Owen D.R., and Lim H.J. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival BMC Cancer 10 2010 59
20. Zhao H., Mandich D., Cartun R.W., and Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas Diagn Cytopathol 35 2007 700 704 (Pubitemid 350035041)
21. Yantiss R.K., Cosar E., and Fischer A.H. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas Acta Cytol 52 2008 133 138 (Pubitemid 351441122)
22. Ligato S., Zhao H., Mandich D., and Cartun R.W. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies Diagn Cytopathol 36 2008 561 567
23. Levy M., Lin F., and Xu H. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy Hum Pathol 41 2010 1210 1219
24. Wagner D.G., Yang Q., and McMahon L.A. IMP3 expression can distinguish cholangiocarcinomas and metastatic pancreatic ductal carcinomas from benign bile duct lesions Mod Pathol 22 2009 324A 325A
25. Lu D., Vohra P., and Chu P.G. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia Am J Surg Pathol 33 2009 521 525
26. Feng W., Truong C.D., Zhai J., Zhou Z., and Tan D. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in human esophageal adenocarcinoma and its precursor lesions Mod Pathol 22 2009 129A
27. Jeng Y.M., Wang T.H., Lu S.H., Yuan R.H., and Hsu H.C. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma Br J Surg 96 2009 66 73
28. Li D., Yan D., and Tang H. IMP3 Is a novel prognostic marker that correlates with colon cancer progression and pathogenesis Ann Surg Oncol 16 2009 3499 3506
29. Yuan R.H., Wang C.C., and Chou C.C. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma Ann Surg Oncol 16 2009 1711 1719
30. Wagner D.G., Yang Q., and McMahon L.A. IMP3 expression can distinguish hepatocellular carcinoma from hepatocellular adenoma Mod Pathol 22 2009 325A
31. Riener M.O., Fritzsche F.R., and Clavien P.A. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas Hum Pathol 40 2009 1377 1383
32. Singh S., Zheng W., and Wang J. IMP3: a novel molecular marker that distinguishes endometrial serous carcinoma from benign and other malignant lesions of the endometrium Mod Pathol 20 2007 214A
33. Zheng W., Yi X., and Fadare O. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma Am J Surg Pathol 32 2008 304 315 (Pubitemid 351172146)
34. Lu D., Zhou Y., and Kamionek M. Expression of IMP3, an oncofetal protein, in various malignant primary and metastatic neoplasms, a study of 1099 cases Mod Pathol 22 2009 340A
35. Li C., Zota V., and Woda B.A. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations Mod Pathol 20 2007 1263 1268 (Pubitemid 350126850)
36. Zhang Y., Garcia M.T., Koru-Sengul T., and Ganjei-Azar P. A panel of immunohistochemical markers to distinguish ovarian from uterine serous papillary carcinomas Mod Pathol 22 2009 242A
37. Zheng W., Kelly M., and Yi X. Endometrial serous carcinoma with a tubuloglandular pattern: an underrecognized form of aggressive endometrial cancer Mod Pathol 20 2007 219A
38. Li C., Rock K.L., and Woda B.A. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression Mod Pathol 20 2007 242 247 (Pubitemid 46422179)
39. Li C., Anderson M.L., and Lisovsky M. Immunohistochemical analysis of IMP3 in ovarian carcinomas: a clinicopathologic study Mod Pathol 20 2007 205A
40. Noske A., Faggad A., and Wirtz R. IMP3 expression in human ovarian cancer is associated with improved survival Int J Gynecol Pathol 28 2009 203 210
41. Zhao F., Zheng W., and Ip P.P.C. The oncofetal protein IMP3 is differentially expressed in clear cell carcinoma of ovary Mod Pathol 22 2009 242A
42. Bellezza G., Cavaliere A., and Sidoni A. IMP3 expression in non-small cell lung cancer Hum Pathol 40 2009 1205 1206
43. Vohra P., Cagle P.T., and Allen T.C. Tissue microarray study of RNA-binding protein IMP3 in primary non-small cell lung cancers: prediction of survival in early stage squamous cell carcinomas Mod Pathol 21 2008 352A
44. Findeis-Hosey J.J., Yang Q., and McMahon L.A. IMP3: an immunohistochemical marker for invasive squamous cell carcinoma and its high-grade precursor lesions of the lung Mod Pathol 23 2010 402A
45. Findeis-Hosey J.J., Yang Q., Spaulding B.O., Wang H.L., and Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma Hum Pathol 41 2010 477 484
46. Xu H., Bourne P.A., Spaulding B.O., and Wang H.L. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not Hum Pathol 38 2007 555 563 (Pubitemid 46399894)
47. Ikeda K., Tate G., Suzuki T., Kitamura T., and Mitsuya T. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology Hum Pathol 41 2010 745 750
48. Hanley K.Z., Facik M.S., and Bourne P.A. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions Cancer 114 2008 49 56 (Pubitemid 351304612)
49. Sojka K.M., Spaulding B., Nielsen G.K., Dinnogen S.A., and Welcher R. Immunoreactivity of anti-L523S on normal and malignant lung pleural tissue biopsies Mod Pathol 19 2006 217
50. Xu H., Simon R., Bourne P.A., Spaulding B.O., and Wang H.L. Immunohistochemical analysis of KOC/IMP3 in malignant pleural mesothelioma Mod Pathol 21 2008 353A
51. LeGolvan M.P., Hao S., and Woda B.A. Insulin-like growth factor-II mRNA-binding protein expression in leukemias and lymphomas Mod Pathol 22 2009 274A
52. Pryor J.G., Bourne P.A., and Yang Q. IMP-3 is a novel progression marker in malignant melanoma Mod Pathol 21 2008 431 437 (Pubitemid 351441031)
53. Yu L., Xu H., Wasco M.J., Bourne P.A., and Ma L. IMP-3 expression in melanocytic lesions J Cutan Pathol 37 2010 316 322
54. Slosar M., Vohra P., and Prasad M. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors Endocr Pathol 20 2009 149 157
55. Jin L., Seys A.R., and Zhang S. Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study Diagn Mol Pathol 19 2010 63 69
56. Asioli S., Erickson L.A., and Righi A. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression Mod Pathol 23 2010 1269 1278
57. Hao S., Smith T.W., and Chu P.G. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma Mod Pathol 22 2009 330A
58. Jiang Z., Chu P.G., and Woda B.A. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas Clin Cancer Res 14 2008 5579 5584
59. Jiang Z., Chu P.G., and Woda B.A. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study Lancet Oncol 7 2006 556 564 (Pubitemid 43923666)
60. Hoffmann N.E., Sheinin Y., and Lohse C.M. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma Cancer 112 2008 1471 1479 (Pubitemid 351441159)
61. Jiang Z., Lohse C.M., and Chu P.G. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas Cancer 112 2008 2676 2682 (Pubitemid 351969211)
62. Mohanty S.K., Lu D.I., Dresser K., and Jiang Z. An oncofetal protein, IMP3: a novel biomarker to predict of tumor progression in the low grade to urothelial carcinoma of the bladder Mod Pathol 21 2008 171A
63. Sitnikova L., Mendese G., and Liu Q. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder Clin Cancer Res 14 2008 1701 1706 (Pubitemid 351469454)
64. Li L., Xu H., and Spaulding B.O. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors Hum Pathol 39 2008 1205 1211
65. Istanvic S., Fanger G.R., and Fraire A.E. Spectrum of KOC (K homology domain containing protein overexpressed in cancer) immunostaining among carcinomas of different sites Mod Pathol 18 2005 298A 299A
66. Hure M.C., Jiang Z., and Lu D. Expression of IMP3 in primary and metastatic breast ductal adenocarcinomas Mod Pathol 22 2009 47A
67. Walter O., Prasad M., and Lu S. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype Hum Pathol 40 2009 1528 1533
68. Jaffar R., Pieters R.S., and Fitzgerald T.J. IMP3, CD44, Ki-67, β-1 integrin, and cyclin-D1 expression in radiation resistant (RR) and radiation sensitive (RS) laryngeal squamous cell carcinomas (SCC) Mod Pathol 21 2008 236A 237A
69. Do S.I., Kim Y.W., Park H.R., and Park Y.K. Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma Oncol Res 17 2008 269 272
70. Li K.H., Huang Y.P., Zhang J., Li G.J., and Li S.H. Expression of IMP3 in osteosarcoma and its clinical significance Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25 2009 426 427
71. Vohra P., Li C., Dresser K., Zona M., and Prasad M.L. RNA-binding protein IMP3 expression in neoplasms of the schneiderian and squamous mucosa of the head and neck Mod Pathol 20 2007 230A
72. Himoto T., Kuriyama S., and Zhang J.Y. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma Int J Oncol 27 2005 1079 1085
73. Himoto T., Kuriyama S., and Zhang J.Y. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma Int J Oncol 26 2005 311 317
74. Toll A.D., Witkiewicz A.K., and Bibbo M. Expression of K homology domain containing protein (KOC) in pancreatic cytology with corresponding histology Acta Cytol 53 2009 123 129
75. Mentrikoski M.J., Ma L., and Pryor J.G. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes Mod Pathol 22 2009 1582 1587
76. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma Expert Rev Mol Diagn 8 2008 557 558
77. Serra S., and Asa S.L. Controversies in thyroid pathology: the diagnosis of follicular neoplasms Endocr Pathol 19 2008 156 165
78. Saleh H.A., Jin B., Barnwell J., and Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules Diagn Pathol 5 2010 9
79. Kapoor S. IMP3: a new and important biomarker of systemic malignancies Clin Cancer Res 14 2008 5640 author reply 5640-1
80. Mueller F., Bommer M., and Lacher U. KOC is a novel molecular indicator of malignancy Br J Cancer 88 2003 699 701 (Pubitemid 36411447)